Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00412516
Status:
COMPLETED
Last Update Posted:
2014-10-13
First Post:
2006-12-14
Brief Title:
Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
Sponsor:
PATH
Organization:
PATH
Study Overview
Official Title:
Long-Term Assessment at 24 Months Post-Vaccination of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine to Measles Vaccine Given Alone
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The previously conducted JEV01 study looked at the immunogenicity and safety of the concurrent administration of Japanese Live Attenuated SA 14-14-2 and measles vaccines at the one month post vaccination time point The purpose of the JEV01 study was to help ensure the safety of SA 14-14-2 simultaneously administered with measles vaccine paving the way for its use in routine EPI programs As a follow-on to JEV01 this study will enroll those infants who received both vaccines and completed the JEV01 study This study however will provide crucial data to help ensure the long-term immunogenicity of the concurrent administration of these vaccines and provide valuable information to determine the use of these vaccines in routine immunization programs This study is planned because in the original protocol for JEV01 long-term data points were not included The hypothesis is that children who receive JE live attenuated SA 14-14-2 vaccine and measles vaccine at the same time have long-term 24 and 36 months post vaccination protection against these diseases at the same level as those who receive the vaccines at different intervals
Detailed Description:
Japanese encephalitis is the leading cause of viral neurological disease and disability in Asia The severity of sequelae together with the volume of cases make JE the most important cause of viral encephalitis in the world Approximately 3 billion people-including 700 million children-live in Asian areas at risk for JE JE most commonly infects children between the ages of 1 and 15 years and can also infect adults in areas where the virus is newly introduced More than 50000 cases are reported annually and cause an estimated 10000 to 15000 deaths This figure is believed to represent only a small proportion of the disease burden that actually exists
An effective vaccine has existed since 1941 but has not reached the poorest countries in Asia During the 60 years that the vaccine has been available JE has infected an estimated 105 million children resulting in more than 3 million deaths and more than 4 million children living with long-term disabilities Control of this disease has been limited due to poor disease surveillance a limited and unstable vaccine supply lack of guidance and programmatic support for immunization and limited advocacy
A successful vaccine should be safe efficacious affordable administered in a single dose and easily incorporated into the routine Expanded Programmes on Immunization EPI programs
This trial is designed to determine the potential interference between the measles vaccine and the Japanese encephalitis vaccine at 12 24 and 36 months post-vaccination As these vaccines will be used in routine EPI systems at the same time similar to how measles and yellow fever vaccine also a Flavivirus are administered it is imperative to collect long-term data showing that neither vaccine interferes with seroconversion of the other when co-administeredThis information will help to ensure subject safety and facilitate programmatic efficiency reducing the number of immunization visits for both parents and health care workers
An effective vaccine has existed since 1941 but has not reached the poorest countries in Asia During the 60 years that the vaccine has been available JE has infected an estimated 105 million children resulting in more than 3 million deaths and more than 4 million children living with long-term disabilities Control of this disease has been limited due to poor disease surveillance a limited and unstable vaccine supply lack of guidance and programmatic support for immunization and limited advocacy
A successful vaccine should be safe efficacious affordable administered in a single dose and easily incorporated into the routine Expanded Programmes on Immunization EPI programs
This trial is designed to determine the potential interference between the measles vaccine and the Japanese encephalitis vaccine at 12 24 and 36 months post-vaccination As these vaccines will be used in routine EPI systems at the same time similar to how measles and yellow fever vaccine also a Flavivirus are administered it is imperative to collect long-term data showing that neither vaccine interferes with seroconversion of the other when co-administeredThis information will help to ensure subject safety and facilitate programmatic efficiency reducing the number of immunization visits for both parents and health care workers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None